Depemokimab going the distance in asthma

8 minute read


Two-year follow-up finds sustained reductions in exacerbations and improvements in asthma control, lung function, and quality of life.


The first ultra-long-acting biologic for asthma has maintained its clinical benefits over two years of treatment, with no evidence of waning efficacy or new safety signals, according to a two-year analysis of two phase 3 trials and their open-label extension.

Depemokimab (Exdensur, GlaxoSmithKline), which is administered by subcutaneous injection every 26 weeks in the 52-week OLE of the SWIFT-1 and SWIFT-2 trials, showed sustained reductions in asthma exacerbations and improvements in lung function, asthma control, and health-related quality of life over 104 weeks in patients with type 2 inflammation and an eosinophilic phenotype.

The integrated analysis found that the annualised exacerbation rate among patients receiving depemokimab throughout the 104-week period remained relatively stable, at 0.51 (95% CI 0.43–0.61) during the initial 52-week trials and 0.56 (0.47–0.66) during the subsequent OLE.

Across the full two-year period, the annualised exacerbation rate was 0.53 (95% CI 0.45–0.61).

Improvements in St George’s Respiratory Questionnaire (SGRQ) total scores, Asthma Control Questionnaire-5 (ACQ-5) scores, and pre-bronchodilator forced expiratory volume in one second (FEV1) were also maintained.

Patients who initially received placebo in the SWIFT-1 and SWIFT-2 trials experienced improvements across clinical outcomes after switching to depemokimab in the extension study.

Further analyses of the original trials indicated that the reduction in exacerbations was maintained throughout the entire 26-week dosing interval, with no evidence that the treatment effect diminished with continued exposure.

While biologics have transformed the management of severe asthma – reducing exacerbations and oral corticosteroid use while improving asthma control, health-related quality of life, and lung function – authors noted that there exist challenges associated with adherence.

Most biologics require administration every two to eight weeks. Depemokimab has enhanced interleukin-5 (IL-5) binding affinity, high potency, and an extended half-life, allowing it to be administered twice yearly while maintaining suppression of type 2 inflammation.

The initial phase 3a SWIFT-1 and SWIFT-2 trials demonstrated that depemokimab significantly reduced exacerbations by 54% over 52 weeks in patients aged 12 years and older with severe asthma and an eosinophilic phenotype.

The reduction was accompanied by sustained suppression of type 2 inflammation, reflected by decreases in blood eosinophil count (BEC) that were observed from two weeks after administration.

Type 2 inflammation with an eosinophilic phenotype account for up to 84% of severe asthma cases.

The original SWIFT-1 and SWIFT-2 trials enrolled patients aged at least 12 years with diagnosed asthma characterised by type 2 inflammation and an eosinophilic phenotype, a history of at least two exacerbations requiring systemic corticosteroids during the previous 12 months, and regular treatment with medium-dose or high-dose inhaled corticosteroids over the same period.

They also required a BEC of at least 150cells/μL at screening or at least 300cells/μL during the previous 12 months, alongside treatment with at least one additional controller for three months or longer. Any ACQ-5 score was acceptable for enrolment.

SWIFT-1 was conducted between March 2021 and November 2023 across 86 sites in 12 countries, while SWIFT-2 ran from February 2021 to April 2024 across 131 sites in 11 countries.

Of the 762 patients randomised in SWIFT-1 and SWIFT-2, 641 met the eligibility criteria and entered the single-arm, 52-week AGILE OLE study, conducted across 156 centres in 14 countries between March 2022 and May 2025.

A total of 629 patients received at least one dose of depemokimab during the extension and were included in the safety analysis: 419 patients who received depemokimab in both the original trials and the extension, and 210 who switched from placebo in SWIFT-1 or SWIFT-2 to depemokimab in AGILE.

Treatment and study completion rate was high: 95% in the depemokimab–depemokimab group and 94% in the placebo–depemokimab group. No patients were withdrawn because of protocol-defined stopping criteria or death.

The placebo-depemokimab group showed improvements across quality of life, lung function, inflammation, and asthma control measures during the OLE, while the depemokimab–depemokimab group maintained the improvements from the initial trials across this period.

For those that switched from placebo to depemokimab, the annualised exacerbation rate decreased from 1.12 (95% CI 0.91–1.38) during the first 52 weeks to 0.58 (95% CI 0.46–0.74) during the AGILE OLE.

Over the extension, least squares mean change from extension baseline was –2.61 (95% CI –3.87 to –1.35) at week 26 (n=379) and –2.31 (95% CI –3.72 to –0.91) at week 52 (n=373) for the depemokimab–depemokimab group, and SGRQ total scores remained improved across the 104-week period.

In the placebo-depemokimab, the least squares mean change from AGILE OLE baseline was –5.03 (95% CI –6.88 to –3.19) at week 26 (n=176) and –4.77 (95% CI –6.82 to –2.72) at week 52 (n=174) and SGRQ total scores improved.

Improvements in pre-bronchodilator FEV1 were also observed throughout the integrated 104-week analysis in both treatment groups.

Among patients receiving depemokimab throughout the study, the least squares mean change from baseline was 195 mL (95% CI 154–235; n=409) at week 52 and 178 mL (95% CI 134–222; n=383) at week 104.

For patients who initially received placebo before switching to depemokimab, the corresponding changes were 158 mL (95% CI 100–216; n=198) at week 52 and 190 mL (95% CI 128–253; n=192) at week 104.

Suppression of eosinophilic inflammation was similarly sustained/improved.

Across the extension cohort, 89% of the depemokimab–depemokimab group and 92% of the placebo–depemokimab group had a BEC of at least 150cells/μL at screening. A BEC of at least 300cells/μL during the preceding 12 months was recorded in 56% and 48%, respectively.

In the depemokimab–depemokimab group, the least squares geometric mean ratio of BEC to baseline remained between 0.128 (95% CI 0.119–0.137) and 0.194 (95% CI 0.181–0.209) throughout the integrated 104-week period.

Among patients who switched from placebo, the ratio to baseline at week 56 – four weeks after commencing depemokimab – was 0.148 (95% CI 0.134–0.164), representing an 85.2% reduction from baseline.

BEC remained suppressed by more than 80% throughout the AGILE OLE in this group, with ratios to baseline ranging from 0.136 (95% CI 0.122–0.151) to 0.191 (95% CI 0.170–0.216).

Asthma control, measured using ACQ-5, also improved across the two-year period.

In the depemokimab–depemokimab group, improvements were maintained throughout the integrated analysis, while patients who initially received placebo experienced further reductions in ACQ-5 scores after commencing depemokimab at week 52.

During the AGILE OLE, the least squares mean change from extension baseline in ACQ-5 score was –0.12 (95% CI –0.20 to –0.05) at week 26 (n=393) and –0.11 (95% CI –0.19 to –0.03) at week 52 (n=381) among patients who continued depemokimab.

In the placebo–depemokimab group, the corresponding changes were –0.14 (95% CI –0.25 to –0.03) at week 26 (n=186) and –0.15 (95% CI –0.27 to –0.04) at week 52 (n=180).

Additionally, the researchers also conducted a post-hoc subgroup analysis of patients with uncontrolled asthma at baseline, defined by an ACQ-5 score of at least 1.5. As the original SWIFT-1 and SWIFT-2 trials did not require participants to have symptomatic asthma at baseline, this analysis was intended to assess outcomes in patients with greater baseline disease activity.

Among patients with uncontrolled asthma who received depemokimab throughout the study, improvements in SGRQ scores were greater than those observed in the overall population at all assessed timepoints.

At week 52, the least squares mean change from the original SWIFT-1 and SWIFT-2 baseline was –15.15 (95% CI –17.06 to –13.25; n=292). This improvement increased further to –16.94 (95% CI –18.93 to –14.95; n=273) by week 104.

In the placebo–depemokimab group, improvements among patients with uncontrolled asthma were similar to those in the overall population, becoming more pronounced after switching to treatment. The least squares mean change was –10.04 (95% CI –12.67 to –7.42; n=150) at week 52 and –15.24 (95% CI –18.02 to –12.47; n=133) at week 104.

Among patients with uncontrolled asthma at baseline, improvements in ACQ-5 were generally greater than those in the overall population.

In the depemokimab–depemokimab group, the least squares mean change from the original trial baseline was –0.90 (95% CI –1.03 to –0.78; n=292) at week 52, increasing to –0.98 (95% CI –1.10 to –0.85; n=281) at week 104.

In the placebo–depemokimab group, improvements became more pronounced after the switch to treatment, with changes of –0.73 (95% CI –0.90 to –0.57; n=150) at week 52 and –0.84 (95% CI –1.01 to –0.67; n=140) at week 104.

Importantly, depemokimab was generally well tolerated throughout the integrated 104-week analysis, with no new safety signals identified.

During the full two-year period, adverse events occurred in 86% of patients in the depemokimab–depemokimab group.

The most frequently reported on-treatment adverse events were covid affecting 25% of patients, nasopharyngitis (23%), and upper respiratory tract infection (16%). Drug-related adverse events, as assessed by investigators, were relatively uncommon, occurring in 6% patients over the 104-week period.

On-treatment serious adverse events were reported in 13% of patients receiving depemokimab throughout the two years. None were considered treatment-related or fatal. Asthma was the most frequently reported serious adverse event, occurring in 3% of patients.

Only two patients (less than 1%) experienced adverse events leading to treatment discontinuation or withdrawal, and neither event was considered related to depemokimab.

During the 52-week AGILE OLE alone, adverse events occurred in 71% in the depemokimab–depemokimab group and 70% in the placebo–depemokimab group. Serious adverse events occurred in 9% of patients in each group, affecting 37 patients who continued depemokimab and 19 who switched from placebo.

Drug-related adverse events were uncommon during the extension, occurring in 4% of patients in the depemokimab–depemokimab group and 2% in the placebo–depemokimab group.

No treatment-related or fatal serious adverse events were reported.

Immunogenicity was assessed to be low, with no substantial increase in anti-drug antibody incidence following an additional year of depemokimab exposure.

During the 52-week AGILE OLE, anti-drug antibodies were detected in 9% of patients overall, with similar rates between treatment groups (10% depemokimab–depemokimab and 7% placebo–depemokimab).

This was on par with the 9% incidence reported among patients receiving depemokimab in the original SWIFT-1 and SWIFT-2 trials.

The authors said the findings supported the potential for depemokimab to provide sustained control of eosinophilic asthma while reducing the frequency of biologic administration.

Further evidence from routine clinical practice will be important in determining whether the benefits observed in the trial setting translate into improved adherence and long-term outcomes across broader patient populations, they concluded.

The Lancet Respiratory Medicine, 29 October 2026

End of content

No more pages to load

Log In Register ×